1. Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, Brinson C, Cyktor J, Jacobs J, Koontz D, Mellors J, Laird GM, Wrin T, Patel H, Guo S, Wallin J, Boice J, Zhang L, Humeniuk R, Begley R, German P, Graham H, Geleziunas R, Brainard DM, SenGupta D. “Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.Clin Infect Dis. 2020 Oct 12:ciaa1534. doi: 10.1093/cid/ciaa1534. Online ahead of print.PMID: 33043969

  2. DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J, Xu J, Felizarta F, Scribner A, Ramgopal M, Benson P, Johns BA.” A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.Clin Infect Dis. 2020 Aug 22;71(5):1255-1262. doi: 10.1093/cid/ciz938.PMID: 31769793

  3. Gantner P, Pagliuzza A, Pardons M, Ramgopal M, Routy JP, Fromentin R, Chomont N. “Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART.Nat Commun. 2020 Aug 14;11(1):4089. doi: 10.1038/s41467-020-17898-8.PMID: 32796830

  4. Ward D, Ramgopal M, Riedel DJ, Garris C, Dhir S, Waller J, Roberts J, Mycock K, Oglesby A, Collins B, Dominguez M, Pike J, Mrus J. “Real-World Experience with Dolutegravir-Based Two-Drug Regimens.AIDS Res Treat. 2020 Jul 7;2020:5923256. doi: 10.1155/2020/5923256. eCollection 2020.PMID: 32724674

  5. Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, Goldstein D, Applin S, Ryu JH, Jiang S, Cox S, Das M, Nguyen-Cleary T, Piontkowsky D, Guyer B, Rossaro L, Haubrich RH. “HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.PLoS One. 2020 Jan 29;15(1):e0224875. doi: 10.1371/journal.pone.0224875. eCollection 2020.PMID: 31995556 

  6. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. “Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.PMID: 31740348 Clinical Trial.

  7. Huhn GD, Crofoot G, Ramgopal M, Gathe J, Bolan R, Luo D, Simonson RB, Nettles RE, Benson C, Dunn K. “Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study.Clin Infect Dis. 2019 Dec 27:ciz1213. doi: 10.1093/cid/ciz1213. Online ahead of print.PMID: 31879782

  8. Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, Warren W, Kleanthous H, Ross TM. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.Hum Vaccin Immunother. 2019;15(9):2030-2043. doi: 10.1080/21645515.2019.1642056. Epub 2019 Aug 8.PMID: 31291153

  9. Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH.”Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.AIDS. 2019 Aug 1;33(10):1583-1593. doi: 10.1097/QAD.0000000000002244.PMID: 31305329 Clinical Trial.

  10. Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, Canon V, Dorey D, Griffith S, Mrus J, Spreen W, Margolis D. “Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.”  HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696. Epub 2019 Sep 18.PMID: 31533539 Clinical Trial.

  11. Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H. “Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5.PMID: 31068270 Clinical Trial.

  12. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. “Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.PMID: 30420123 Clinical Trial.

  13. Huhn G, Crofoot G, Ramgopal M, Gathe J, Bolan R, Luo D, Simonson R, Nettles R, Dunn K. “Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) Rapid Initiation for HIV-1 Infection: Primary Analysis of the Diamon Study at ACTHIV.” 13th Annual American Conference for the Treatment of HIV (ACTHIV); April 11-13, 2019; Miami, Florida
  14. DeJesus, E., Haas, B., Segal-Maurer, S., Ramgopal, M., Mills, A., … McCallister, S. “Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate (TDF)- to a Tenofovir Alafenamide (TAF)-based Regimen through 96 weeks of Treatment.
  15. Orkin C, DeJesus E, Ramgopal, M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu H, Cheng A, Quirck E, SenGupta D, Cao H. “Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated with Rilpivirine and Emtricitabine in Virally Suppressed Adults with HIV-1 Infection: A Randomised, Double-Blind, Multicentre, Phase 3B, Non-Inferiority Study” The Lancet HIV May 2017; Volume 4, Issue 5, Pages e195-e204
  16. DeJesus E, Ramgopal, M, Crofoot G, Ruane P, LaMarca A, Mills A, Martorell C, de Wet J, Stellbrink H, Molina J, Post F, Valero I, Porter D, Liu Y, Cheng A, Quirk E, SenGupta D, Cao H. “Switching from Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated with Rilpivirine and Emtricitabine in Virally Suppressed Adults with HIV-1 Infection: A Randomized, Double-Blind, Multicentre, Phase 3B, Non-Inferiority Study” The Lancet HIV May 2017; Volume 4, No. 5, e205-e213
  17. Kuretski J, Dahya V, Cason L, Chalasani P, Ramgopal, M. “Nocardia Bacteremia and Endocarditis in a Patient with a Sulfa Allergy” The American Journal of the Medical Sciences November 2016; Volume 352, Issue 5, P 542-543.
  18. DeJesus E, Elion R, Ramgopal, M, Wade B, Sloan L, Edelstein H, Pierone G, Slim J, Stephens J, Yan M, Tran-Muchowski C, Rhee M. “Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Black Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study” Open Forum Infectious Diseases 25 October 2016
  19. Brown S, Berger R, Ramgopal, M, Dahya V. “Tuberculosis Infection Status Post Partial Knee Arthroplasty: A Novel Treatment Approach” Infectious Diseases in Clinical Practice November 2016; Volume 24, Issue 6, P 350-351.
  20. Luetkemeyer A, Mcdonald C, Ramgopal, M, Noviello S, Bhore R, Ackerman P. “12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens” Clinical Infectious Diseases Jun 29, 2016; 62(12):1489-96. Epub Mar 29, 2016
  21. Ramgopal, M, Osiyemi O, Zorrilla C, Crauwels H, Ryan R, Brown K, Hillewaert V, Baugh B. “Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.” Journal of Acquired Immune Deficiency Syndromes May 6, 2016. Epub May 6, 2016.
  22. Arevalo M, Kirchenbaum G, Lanteri M, Stramer S, Ramgopal, M, Ross T. “Dengue Outbreak in Martin County, Florida in 2013.” Journal of Human Virology & Retrovirology 3(1) December 14, 2015.
  23. Pozniak A, Arribas J, Gathe J, Gupta S, Post F, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal, M, Chetchotisakd P, Custodio J, Abram M, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce M. “Switching to Tenofovir Alafenamide, Coformulated with Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients with Renal Impairment; 48 Week Results from a Single-Arm, Multi-Center, Open-Label, Phase 3 Study. JAIDS Journal of Acquired Immune Deficiency Syndromes November 30, 2015; DOI:10.1097/QAI.0000000000000908
  24. Wyles, D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer A, Morgan T, Sherman K, Dretler R, Fishbein D, Gathe J, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton E, Ramgopal, M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin P, Noviello S, Ackerman P. “Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.” New England Journal of Medicine August 21, 2015; 373 (8): 714-25. Epub July 21, 2015.
  25. McDonald CK, Martorell C, Ramgopal, M, Laplante F, Fisher M, Post FA, Liu Y, Curley J, Abram ME, Custodio J, Graham H, Rhee MS, Szwarcberg J. “Cobicistat (COBI)-boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment.” HIV Clinical Trials 2014 Nov-Dec; 15(6):269-73. doi: 10.1310/hct1506-269.
  26. Ruane PJ, Brinson C, Ramgopal, M, Ryan R, Coate B, Cho M, Kakuda TN, Anderson D. The Intelence and Prezista Once A Day Study (INROADS): A multicentre, single-arm, open-label study of Etravirine and Darunavir/Ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects. HIV Medicine (2014). Doi: 10.1111/hiv.12211
  27. Akil B, Blick G, Hagins D, Ramgopal, M, Richmond G, Samuel R, Givens N, Vavro C, Song I, Wynne B, Ait-Khaled M, the VIKING-4 study team. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antiviral Therapy (2015) 16;20(3):343-8. Epub 16 October 2014.
  28. Vandergeeten C, Fromentin R, Merlini E, Bramah-Lawani M, DaFonseca S, Bakeman W, Ramgopal, M, Michael N, Kim J, Ananworanich J, Chomont N. Cross-clade Ultrasensitive PCR-based Assays to Measure HIV Persistence in Large Cohort Studies. Journal of Virology 13 August 2014. doi: 10.1128/JVI.00609-14
  29. Dahya V, Kulvir N, Chalasani P, Ramgopal, M, Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy National AIDS Treatment Advocacy Project 2014.
  30. Dahya V, Chalasani P, Ramgopal, M. Peptostreptococcus Endocarditis presenting as Lumbar Discitis in an Immunocompromised Patient. The American Journal of Medical Sciences (2014).
  31. Dahya V, Collin B, Ramgopal, M, Robinson M. Clostridium Ramosum Osteomyelitis in an Immunocompetent Patient After Traumatic Injury. Infectious Diseases in Clinical Practice (2014).
  32. Akil B, Blick G, Hagins D, Ramgopal M, Richmond G, Samuel R, Givens N, Vavro C, Song I, Wynne B, Ait-Khaled M, for the VIKING-4 study team. Dolutegravir Versus Placebo in Subjects with Raltegravir- and/or Elvitegravir-Resistant HIV-1 Virus: 48-Week Results from VIKING-4, a Randomized Study.  
  33. Dahya V, Boss T, Ramgopal, M Mycobacterium Bovis Cervical Discitis as a Complication of Intravesicular BCG Irrigation Treatment. Infectious Diseases in Clinical Practice (2014).
  34. McDonald C, Martorell C, Ramgopal, M, Laplante F, Fisher M, Post F, Liu Y, Curley J, Abram M, Custodio J, Graham H, Rhee M, Szwarcberg J. Efficacy of Cobicistat (COBI) boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment. Journal of HIV Clinical Trials
  35. Dahya V, Ramgopal, M, Glickman J. Paradoxical immune reconstitution inflammatory syndrome presenting as acute respiratory distress syndrome in a non-HIV immunosuppressed  sarcoidosis patient. Int J Rheum Dis. 2014 Apr 7. doi: 10.1111/1756-185X.12373.
  36. Dahya V, Ramgopal, M, Collin B. Concomitant Pseudomonas Discitis from Shared Needles in Intravenous Opioid Abusers. Infectious Diseases in Clinical Practice (2014).
  37. Teets F, Ramgopal, M, Sweeney K, Graham A, Michael S, Isern S. Origin of the Dengue Virus Outbreak in Martin County, Florida, USA 2013. Virology Reports doi: 10.1016/j.virep.2014.05.001
  38. Durkin ML, Marchese D, Robinson MD, Ramgopal, M. Catastrophic Antiphospholipid Syndrome (CAPS) Induced by Influenza A Virus Subtype H1N1. BMJ Case Rep. 2013 Sep 30;2013. pii: bcr2013200474. doi: 10.1136/bcr-2013-200474.
  39. Ramgopal, M, contributor to National Guidelines for Management of HIV-Infected and HIV-Exposed Adults and Children in Guyana. January 2009.
  40. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker Pl, International HIV Controllers Study, Ramgopal, M (collaborator). Fine-Mapping Classical HLA Variation Associated with Durable Host Control of HIV-1 Infection in African Americans. Hum Mol Genet. 2012 Oct 1;21(19):4334-47. doi: 10.1093/hmg/dds226. Epub 2012 Jun 19.
  41. Intelence and Prezista Once A Day Study (INROADS); A Multicenter, Single-Arm, Open-Label Study of Etravirine and Darunavir/Ritonavir as Dual Therapy in HIV-1-Infected Early Treatment-Experienced Subjects. Accepted for Publication.
  42. The Major Genetic Determinants of HIV-1 Control Affect HLA Class 1 Peptide Presentation. Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science. 1195271. Epub 2010 Nov 4
  43. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K, GRACE Study Group, Ramgopal M (collaborator). Sex-Based Outcomes of Darunavir-Ritonavir Therapy; A Single-Group Trial.
  44. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buedia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J , Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; on behalf of the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet 2013 Jul 2. Doi:pii; S0140-6736(13)6 1221-0.
  45. Longardner K , Allen A, Ramgopal M. Spinal Osteomyelitis due to Mycobacterium Fortuitum in a former intravenous drug user. BMJ Case Rep 2013 Jul 10, 2013 doi:pii bcr2013010326
  46. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. Interleukin -7 promotes HIV persistence during antiretroviral therapy. Blood. 2013 May 23;121(21):4321-9. Doi: 10.1182/blood-2012-11-465625. Epub 2013 Apr 15.
  47. Dowdy L, Ramgopal M, Hoffman T. Three Cases of Genitourinary Tuberculosis in Renal Transplant Recipients. Clinical Infectious Diseases February 2001.

In The News